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Abstract 
The antileukemic drug asparaginase, a key component in the treatment of acute lymphoblastic 
leukemia, acts by depleting asparagine from the blood. However, little is known about its 
pharmacokinetics and mechanisms of therapy resistance are poorly understood. Here, we explored 
the in vivo biodistribution of radiolabeled asparaginase, using a combination of imaging and 
biochemical techniques, and provide evidence for tissue specific clearance mechanisms, which could 
reduce effectiveness of the drug at these specific sites.  
Methods. In vivo localization of Indium-111-labeled E.coli asparaginase was carried out in C57Bl/6 
mice by both microSPECT/CT and by ex vivo biodistribution studies. Mice were treated with 
liposomal clodronate to investigate the effect of macrophage depletion on tracer localization and 
drug clearance in vivo. Moreover, macrophage cell line models RAW264.7 and THP-1, as well as 
knockout mice, were used to identify the cellular and molecular components controlling 
asparaginase pharmacokinetics. 
Results. In vivo imaging and biodistribution studies showed a rapid accumulation of asparaginase in 
macrophage-rich tissues such as liver, spleen and in particular bone marrow. Clodronate-mediated 
depletion of phagocytic cells markedly prolonged the serum half-life of asparaginase in vivo and 
decreased drug uptake in these macrophage rich organs. Immunohistochemistry and in vitro binding 
assays confirmed the involvement of macrophage-like cells in the uptake of asparaginase. We 
identified the activity of the lysosomal protease cathepsin B in macrophages as a rate-limiting factor 
in degrading asparaginase both in vitro and in vivo. 
Conclusion. We show that asparaginase is rapidly cleared from the serum by liver, spleen and bone 
marrow-resident phagocytic cells. As a consequence of this efficient uptake and protease mediated 
degradation, particularly bone marrow resident macrophages may provide a protective niche to 
leukemic cells. 
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Introduction 
The therapeutic enzyme asparaginase is an essential component of the multi-drug regimen used in 
the treatment of children and adults with acute lymphoblastic leukemia (ALL). Upon administration, 
this drug converts serum asparagine into aspartate, thereby effectively depleting the blood from this 
amino acid. Unlike most other cells in the body, lymphocytes, including leukemic blasts, are fully 
dependent on uptake of asparagine from the blood and die as a result of nutrient stress 1. 
The effectiveness of asparaginase treatment relies on the complete depletion of asparagine from the 
leukemic cell niche. It has been suggested that during asparaginase treatment, leukemic cell survival 
is supported by asparagine released by surrounding mesenchymal cells 2, 3. Although asparagine 
levels are significantly higher in bone marrow aspirates when compared to matched blood samples, 
these levels drop upon treatment with asparaginase 4, 5. However, analyses of aspirates may not 
accurately reflect asparagine concentrations in situ. 
Despite the fact that asparaginase has been a cornerstone of ALL treatment protocols since its 
introduction in the 1970s, little is known about the fate of the infused asparaginase and the 
mechanisms that determine the pharmacodynamics of this drug. With a molecular weight of 170 kDa 
that greatly exceeds the limits for renal filtration (~60 kDa), mononuclear phagocyte system (MPS) 
based (or reticulo-endothelial) clearance is the suggested mode of degradation6.  
Furthermore, the intracellular/molecular mechanisms that influence asparaginase pharmacokinetics 
remain poorly understood. One study showed that the lysosomal cysteine proteases legumain (or 
Asparagine Endopeptidase (AEP)) and cathepsin B efficiently degrade asparaginase in vitro 7. 
Consistent with these observations, we recently identified a patient carrying a germline mutation in 
cathepsin B who showed strongly delayed asparaginase degradation 8. However, further validation of 
these findings and their clinical implications is needed. 
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In the present study we used microSPECT/CT imaging to visualize the in vivo distribution of 111Indium-
labeled asparaginase in a mouse model and identified both cellular and molecular components that 
determine asparaginase pharmacokinetics. 
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Materials and Methods 
Mouse models 
All animal experiments were approved by the Animal Experimental Committee of the Radboud 
university medical center and performed in accordance with institutional and national guidelines. 
Wildtype C57Bl/6J mice were obtained from Charles River (Leiden, the Netherlands). Cathepsin B 
knockout mice were described previously 9 and have been backcrossed to C57Bl/6J for 10 
generations. All mice were housed in individually ventilated filter-top cages, and a standard diet and 
water were provided ad libitum. The mice were used between ages 8 and 10 weeks.  
Micro-SPECT/CT imaging 
Mice were injected intravenously with 3 I.U. / gram of bodyweight of 111In-DTPA-asparaginase (21-24 
MBq/mouse in 200 μL, see supplemental methods for labeling procedure) and scanned under 
anesthesia (isoflurane/O2) at indicated time points after injection using the U-SPECT-II/CT ((MILabs, 
Utrecht, the Netherlands 10). CT scans (spatial resolution 160 µm, 65 kV, 615 µA) were acquired for 
anatomical reference. SPECT scans, (3 frames of 17 min), were reconstructed using an ordered-
subset expectation maximization algorithm, with a voxel size of 0.4 mm. SPECT images were analyzed 
quantitatively as described previously11. 
Biodistribution experiments 
Mice were injected intravenously with 3 I.U. 111In-DTPA-asparaginase / gram of bodyweight. Mice 
were euthanized by CO2/O2 asphyxiation at the indicated times after injection. Blood and major 
organs and tissues were dissected, weighed, and counted in a gamma counter. In addition, organs 
were used for autoradiography and immunohistochemical analysis (see supplemental methods for 
procedures). 
Pharmacokinetics experiments 
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Mice were injected intravenously with 3 I.U. Asparaginase/gram of bodyweight (Takeda, Hoofddorp, 
the Netherlands). At the indicated times after injection, mice were euthanized by CO2/O2 
asphyxiation, a blood sample was drawn and tissues of interest were dissected. When indicated, 
mice were pretreated with 150 μl (1 mg/ml clodronate) liposomes or control liposomes 12 via tail vein 
injection 24 hours before administration of 111In-labeled asparginase. Residual asparaginase activity 
in serum was determined by photometric detection of the ammonia release after reaction with 
Nessler’s reagent (Sigma-Aldrich, Gorinchem, the Netherlands). In brief, 15 µl serum was diluted with 
60 µl 44 mM L-asparagine (Sigma-Aldrich) dissolved in 15 mM Tris-HCl buffer, pH 7.3, supplemented 
with 0.015% (w/v) BSA and incubated at 37 °C for 30-45 min. The reaction was stopped by the 
addition of 50 µl trichloroacetic acid (24.5% (w/v), Sigma-Aldrich). After centrifugation 15 µl of the 
supernatant was added to 120 µl Nessler’s solution diluted with deionized water (1:8). The optical 
density of the solution was measured at 450 nm using the Multiskan Ascent plate reader (MTX Lab 
systems, Vienna, VA).  
Cathepsin B activity assay 
Cathepsin B activity was measured using the fluorescent substrate Ac-RR-AFC according to 
manufacturer’s instructions (BioVision, San Francisco, CA). Prism software was used to plot the data 
and for statistical analysis. p< 0.05 was considered a significant difference. 
Asparaginase degradation assay 
THP-1 and RAW264.7 cells (see supplemental methods for culture conditions) were lysed by freeze-
thawing in degradation buffer (50 mM trisodium citrate buffer, pH 4.5, 5 mM DTT), cleared by 
centrifugation. For each timepoint, 5 I.U./ml asparaginase was incubated in lysate containing 20 µg of 
protein. Where indicated, 1 µM Ca-074 (Sigma-Aldrich) was added to inhibit cathepsin B activity. 
After incubation, asparaginase activity was determined by photometric detection of the ammonia 
release after reaction with Nessler’s reagent using the Multiskan Ascent plate reader as described 
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above. Prism software was used to plot the data and for statistical analysis. ANOVA was used to test 
for significance; p< 0.05 was considered a significant difference. 
shRNA mediated knockdown 
For lentiviral transduction, HEK293FT cells were transfected with one lentiviral pLKO.1-puro vector 
(Dharmacon / GE Healthcare), see Supplemental Table 1 for shRNA sequences) together with pVSV-G 
and psPAX2 using Lipofectamine 2000 (Invitrogen). THP-1 cells were transduced in the presence of 
8µg/mL polybrene and 24 hours after transduction selected with 1µg/mL puromycin (Sigma-Aldrich).  
See supplemental method section for details on the asparaginase binding assay, immunoblotting 
and RT-qPCR. 
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 Results 
MicroSPECT/CT and biodistribution of Asparaginase 
To gain more insight into the in vivo distribution of asparaginase and its degradation, we injected 
mice with 111In-labeled asparaginase and monitored its biodistribution (Figure 1, Supplemental Movie 
1). Imaging (Figure 1A) and ex vivo biodistribution (Figure 1B) data showed similar trends. Two hours 
after injection, asparaginase was mainly present in the circulation (15.8 ± 1.4 %ID/g). However, 
already at this time point we observed accumulation in the liver (8.5 ± 0.4 %ID/g) and spleen (21.1 ± 
3.6 %ID/g), the organs in which a large part of the phagocytic cells reside that make up the MPS 
(Figure 1B). Additionally, we observed that a significant part of radiolabeled asparaginase label 
rapidly localized to the skeleton (femur at 2 hours post injection: 13.0 ± 4.0 %ID/g), suggesting active 
uptake by bone marrow resident cells. Over time, the radiolabeled drug levels decreased in the blood 
pool, but drug uptake in the femur remained stable (at 19 hours post injection: 14.6 ± 1.7 %ID/g) and 
increased in the spleen (42.1 ± 15.9 %ID/g) and liver (10.5 ± 1.5 %ID/g). (Figure 1B).  
Quantitative SPECT analysis revealed an almost identical in vivo distribution as determined by ex vivo 
biodistribution (Figure 1C, Supplemental Figure 1). For instance, radiolabeled asparaginase cleared 
rapidly from the blood and increased in the spleen over time (7.9 ± 1.9 %ID/g and 13.8 ± 3.8 %ID/g at 
2 and 19h post injection, respectively). Uptake of 111In-asparaginase in the femur and sternum 
remained unaltered at 2 (10.1 ± 2.4 %ID/g) and 19h (11.5 ± 2.0 %ID/g) post injection. Quantitative 
SPECT data and biodistribution data correlated well as shown in Figure 1D (Spearman r at 0.7996). 
Autoradiography (Supplemental Figure 2A) and immunohistochemical analysis using anti-
asparaginase antibodies (Supplemental Figure 2B) were used to study asparaginase localization in 
more detail. This revealed accumulation of asparaginase in the bone marrow in spinal cord and hind 
legs. Uptake in the spleen was restricted to the macrophage-rich structure known as red pulp. The 
accumulation of asparaginase in the kidney was limited to the cortex of this organ, consistent with 
glomerular entrapment. The asparaginase immune stainings showed a similar pattern to that of the 
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macrophage marker F4/80 , suggesting that macrophage-like cells are responsible for the uptake. 
Together these results point towards a crucial role for phagocytic cells in liver, spleen and bone 
marrow in the clearance of asparaginase.  
Macrophage depletion by clodronate liposomes disrupts asparaginase biodistribution 
To further study the role of phagocytic cells for asparaginase biodistribution and turnover, we used 
clodronate liposomes to deplete phagocytic cells from the organs of interest. We observed an almost 
complete depletion of F4/80 positive macrophages in liver and spleen and a marked decrease of the 
numbers of macrophages in bone marrow (Supplemental Figure 3) 24 hours after injection of 
clodronate liposomes. Clodronate pretreatment significantly prolonged the serum half-life of 
asparaginase (Figure 2A). MicroSPECT/CT (Figure 2B and Supplemental Movie 2) and ex vivo 
biodistribution assays (Figure 2C) confirmed that clodronate pre-treatment markedly affected the in 
vivo distribution of asparaginase. SPECT scans of control mice were similar to those obtained in 
previous experiments (data not shown). In contrast, in clodronate-treated mice, asparaginase was 
still detectable in the circulation, while little activity was observed in liver (2.5 ± 0.4 %ID/g) and 
spleen (3.2 ± 0.5 %ID/g), indicating a near complete block in asparaginase uptake by these organs. 
Furthermore, accumulation in the bone marrow was significantly diminished (femur: 7.2 ± 4.5 %ID/g; 
spine: 2.2 ± 0.5 %ID/g; sternum: 2.8 ± 0.9 %ID/g), which is consistent with the partial depletion of 
macrophages in this tissue (Supplemental Figure 3e,f). Together our results establish a central role 
for phagocytic cells in the regulation of asparaginase pharmacokinetics.  
Assessment of the biological clearance mechanism 
Our data indicate highly efficient uptake of asparaginase by murine phagocytic cells. To determine 
whether these findings could be replicated with human cells, we incubated freshly isolated PBMCs 
from healthy volunteers with FITC-labeled asparaginase and used flow cytometry to assess which 
cells bind/internalize asparaginase. Consistent with our observations in mice, predominantly cells 
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expressing the monocyte/macrophage marker CD14 (76.4 ± 14.8 %) were found to bind asparaginase 
(Figure 3B).  
In an earlier study, we identified lysosomal protease cathepsin B as a critical determinant of 
asparaginase half-life 8. In order to link this observation to the potential role for phagocytic cells 
identified here, we studied the role of cathepsin B in macrophage-mediated degradation of 
asparaginase. To this end, we used THP-1 cells, a human monocytic cell line that can be forced into 
differentiation towards a macrophage like phenotype using phorbol-12-myristate-13-acetate (PMA). 
Similar to freshly isolated CD14+ cells, THP-1 cells efficiently bound asparaginase (Supplemental 
Figure 4). We used a previously described in vitro degradation assay 8 to show that asparaginase 
activity remained unaffected in the monocyte lysate, while the protein was rapidly degraded in 
lysates from differentiated cells. We observed a similar, but even more efficient degradation in 
lysates of the murine macrophage cell line RAW264.7. Importantly, degradation in both macrophage 
lysates was completely inhibited by the addition of the cathepsin B inhibitor CA-074 (Figure 3C, red 
marked values). 
To investigate the correlation between cathepsin B expression and asparaginase degradation, we 
compared cathepsin B mRNA expression levels in undifferentiated versus differentiated THP-1 cells, 
(Figure 4A) and found that cathepsin B mRNA expression is strongly induced upon differentiation. 
RNAi mediated suppression of cathepsin B activity (Figure 4B and Supplemental Figure 5A and B) 
resulted in a complete or partial block of asparaginase degradation, depending on knockdown 
efficiency (Figure 4C). Furthermore, we observed that the serum half-life of asparaginase was 
strongly prolonged in cathepsin B knockout mice compared (Figure 4D). Together, these data firmly 
establish that cathepsin B activity is an essential and a rate-limiting enzyme for asparaginase 
degradation by macrophages. 
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Discussion  
Although asparaginase has been used for decades in the treatment of patients with ALL, little is 
known about its metabolic fate in patients. Although depletion of asparagine in serum and bone 
marrow aspirates can be monitored and shows complete depletion when asparaginase 
concentrations reach threshold levels, concentrations in situ and the supportive role of the 
microenvironment are subject of debate 2, 3, 5, 13-16. The question remains whether asparaginase is 
sufficiently active at this particular niche where the leukemia originates and where leukemia-
initiating cells reside. 
We applied in vivo imaging of radiolabeled asparaginase with microSPECT/CT to visualize 
asparaginase biodistribution. In addition to spleen and liver, both organs most frequently involved in 
uptake of foreign (macro)molecules and particles, we found a remarkably rapid and strong 
accumulation of asparaginase in the bone marrow. Although bone marrow resident macrophages are 
part of the MPS, the role of these cells in clearing the blood from macromolecules is often secondary 
to spleen and liver resident cells and is directed by the size of the molecule 17, 18. Because for its 
therapeutic action, asparaginase needs to be present in the serum, this raises the question whether 
rapid clearance of the drug by bone marrow resident macrophages will negatively affect the 
depletion of asparagine in the bone marrow niche. Hence, our imaging approach may reflect a rapid 
local elimination of the drug that could provide a mechanism by which leukemic cells can escape 
from apoptosis as a result of the asparaginase induced nutrient limitation. 
Only a few studies have addressed the potential molecular mechanisms involved in the regulation of 
asparaginase kinetics. We show a highly efficient uptake of asparaginase by phagocytic cells, 
predominantly macrophages. These cells express a large variety of antigen uptake receptors that 
recognize macromolecules based on charge, peptide structure or modification, which are 
subsequently internalized and degraded in the endosomal compartment 19. Previous reports discuss 
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the role of lysosomal proteases in controlling asparaginase degradation in vitro and in vivo 7, 8. Our 
recent finding that the prolonged half-life of asparaginase in a pediatric patient suffering from ALL 
could be attributed to a germline mutation in the cathepsin B 8, is now further supported by the in 
vitro and in vivo experiments presented here. Since lysosomal processing of epitopes is a crucial step 
towards successful antigen presentation, blocking cathepsin B mediated degradation by altering the 
amino acid sequence of asparaginase may enhance the therapeutic efficacy of this drug by reducing 
the immunogenicity.  
We have limited our studies to E.coli asparaginase. Two other formulations are in use in clinic 
practice. Erwinia chrysamthemi asparaginase is frequently used as a second line treatment option 
after development of inhibitory antibodies. In our previous study 8, we showed that the kinetics of 
E.coli and Erwinia asparaginase are similarly affected by a mutation in cathepsin B. In addition to its 
native form, a PEGylated form of E.coli asparaginase, which was introduced to reduce 
hypersensitivity reactions to the drug, is widely used in the clinic. The PEG coat reduced the 
immunogenicity due to its shielding properties: it inhibits direct, primarily charge mediated, binding 
of the protein to cells and prevents opsonization. Indeed, patients treated with PEG-asparaginase 
develop anti-asparaginase antibodies less frequently than patients treated with the native form 20. 
Another most welcome effect of the PEGylation of asparaginase, is the prolonged half-life of this 
modified drug. This is consistent with our findings that the interaction between asparaginase and 
phagocytic cells is a critical determinant of the pharmacokinetics. 
With an increased use of PEGylated drugs, not limited to asparaginase, it has become clear that 
patients do develop anti-PEG antibodies and that this can compromise therapeutic efficacy 21-24. 
Therefore, use of PEG-asparaginase should also be supported by therapeutic drug monitoring to 
prevent underexposure25 and as a result, the benefits compared to the use of native asparaginase are 
reduced.  
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Several studies have shown that the structure of asparaginase permits the introduction of 
modifications without appreciable loss of enzymatic function 7, 26, 27. The data we present here may 
provide a rationale for the generation of novel modified versions of asparaginase that may no longer 
require PEGylation. Since our data show that phagocytic cells are an important sink for asparaginase 
as well as a key determinant of the asparaginase pharmacokinetics, preventing these interactions, by 
other means than PEGylation, could be of potential benefit. A modified form of asparaginase that 
exhibits a reduced affinity for such macrophage receptors is expected to have a prolonged half-life, 
show delayed clearance from the bone marrow and thus enhanced therapeutic efficacy.  
In addition, we have shown that lysosomal protease cathepsin B is required for the efficient 
degradation of asparaginase by macrophages. Our in vivo studies demonstrate that loss of cathepsin 
B leads to a significantly prolonged asparaginase half-life in vivo, while inhibition of cathepsin B 
activity completely abolishes its degradation in vitro. While the incomplete depletion of phagocytic 
cells may explain the partial block of asparaginase turnover in the clodronate-treated mice, why 
cathepsin B knockout mice only display a delayed clearance, remains unclear. However, these results 
are in accordance with our previous report, which linked a germline loss-of-function mutation in the 
gene encoding cathepsin B to a prolonged serum half-life of asparaginase in a pediatric patient 8.  
Conclusions 
By using microSPECT/CT we showed that asparaginase is efficiently cleared by macrophages of the 
MPS. In particular, bone marrow resident macrophages may provide a protective environment for 
leukemic cells by effectively removing the therapeutic protein from the bone marrow niche. We 
conclude that cathepsin B is required for the degradation of asparaginase by macrophages, and that 
this degradation aids in the regulation of serum half-life. These new insights into both the prominent 
role of macrophages and the importance of the lysosomal protease cathepsin B in asparaginase 
clearance may aid in a rational design of a next generation asparaginase.   
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FIGURE 1. Asparaginase rapidly accumulates in spleen, liver and bone marrow 
A Ventral (a-d) and lateral (e,f) 3-dimensional volume projections of fused SPECT/CT scans of mice injected 
with 111Indium-labeled asparaginase at the indicated hours post injection (h.p.i.). 
B Ex vivo quantification of 111Indium-labeled asparaginase uptake in various organs at the indicated hours 
post injection (h.p.i.). Data represent mean ± SEM of n = 5 mice per timepoint.  
C Biodistribution of asparaginase as quantified from SPECT images. N=3 per timepoint. 
D Uptake of 111Indium-labeled asparaginase as quantified from micro-SPECT images plotted against values 
derived from ex vivo biodistribution studies. 
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FIGURE 2. Depletion of macrophages affects asparaginase pharmacokinetics and biodistribution 
A Residual serum asparaginase activity at the indicated times after injection in mice. Mice were treated 
with a single dose of control or clodronate liposomes 24 hours prior to the asparaginase injection. At the 
indicated times after injection of unlabelled asparaginase, serum samples were taken and asparaginase 
activity was determined as described in the methods section. Data represent mean ± SEM of n = 3 mice 
per time point per treatment group. ANOVA statistical analysis was applied to test for significance. 
B Ventral 3-dimensional volume projections of fused SPECT/CT scans of mice treated with a single dose of 
control or clodronate liposomes 24 hours prior to the 111Indium-labeled asparaginase injection. Scans were 
made at 7 or 19 hours post injection (h p.i) with 111Indium-labeled asparaginase. 
C Ex vivo quantification of 111Indium-labeled asparaginase uptake in various organs of mice pretreated 
with control or clodronate liposomes, 19 hours post injection (h p.i.) of asparaginase. Data represent mean 
± SEM of n = 5 mice per time point per treatment group. Statistical significance was determined by 
unpaired two-sided t-test. * = p < 0.05, ** = p < 0.01, *** = p < 0.001. 
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FIGURE 3. Human macrophages bind and degrade asparaginase 
A Histograms showing binding of asparaginase to various cellular subsets in PBMCs. Freshly isolated PBMCs 
were incubated with FITC-labelled asparaginase and subsequently indentified based on the indicated cell 
surface markers using flowcytometry. Lineages were defined as follows: CD45-all nucleated cells, CD14-
monocytes/macrophages, CD3-T cells, CD19-B cells. 
B Average of percentage of PBMC subsets binding FITC-labeled asparaginase (N=2). 
C Asparaginase degradation in lysates of cell lines. Asparaginase was incubated in lysate of human 
undifferentiated, monocyte like THP-1 cells (squares), differentiated, macrophage like THP-1 cells (circles) 
and the murine macrophage cell line RAW264.7 (triangles). After incubation, residual ASNase activity was 
assayed as described in the methods section. Cathepsin inhibitor CA-074 was included to selected samples to 
confirm the contribution of Cathepsin B in this degradation (red data points). 
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FIGURE 4. Cathepsin B is required for asparaginase degradation and controls asparaginase 
pharmacokinetics 
A Realtime quantitative PCR analysis of Cathepsin B mRNA expression in undifferentiated and PMA 
induced differentiated THP-1 cells, normalized for expression of TATA binding protein. Data represent 
mean ± SEM of n = 4. Statistical significance was determined by unpaired two-sided t-test. ** = p < 0.01. 
B Realtime quantitative PCR analysis of Cathepsin B mRNA expression in undifferentiated and PMA 
induced differentiated THP-1 cells transduced with shRNAs targeting Cathepsin B or control, non-
targeting (NT) shRNA. Data are normalized for TBP expression and shown as mean ± standard deviation 
of n = 2. Statistical significance was determined by unpaired two-sided t-test. ** = p < 0.01. 
C Asparaginase degradation in lysates of cell lines. Asparaginase was incubated in lysate of 
differentiated THP-1 cells, transduced with control of Cathepsin B targeting shRNAs. After incubation, 
residual ASNase activity was assayed as described in the methods section. A representative example of 
multiple experiments (N=3) is shown. 
D Residual serum asparaginase activity at the indicated times after injection in mice. Cathepsin B 
knockout mice and age and sex matched control were injected with unlabelled asparaginase. At the 
indicated times after injection of unlabelled asparaginase, serum samples were taken and asparaginase 
activity was determined as described in the methods section. Data represent mean ± standard deviation 
of n = 2 mice per time point per treatment group. ANOVA statistical analysis was applied to test for 
significance. 
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Supplemental Figure 1. Calibration of qSPECT quantification 
Calibration curve of a dilution series of 111Indium-labeled asparaginase, determining the voxel intensity per 
µCi of activity. 
S2A 
S2B 
Liver Spleen Bone marrow
A
sp
a
ra
gi
n
a
se
F4
/8
0
Supplemental Figures 
Supplemental Figure 2. Asparaginase is taken up in macrophage-rich parts of spleen, liver and bone marrow  
S2A Autoradiography (upper image) and hematoxylin and eosin stain staining (lower image) of 111Indium-labeled 
asparaginase. Images show kidney (a), spine (b), hind leg bones (c), spleen (d) and liver (e). 
S2B B Immunohistochemical staining of asparaginase and macrophage marker F4/80 in organs dissected from 
mice 9-15 hours post injection of unlabelled asparaginase. Images show two representative magnifications of 
liver, spleen and femoral bone marrow. 
Supplemental Figures 
S3 
Supplemental Figure 3. Immunohistochemical analysis of clodronate mediated macrophage 
depletion 
Immunohistochemical staining of macrophage marker F4/80 in organs dissected from mice 9-15 hours 
post injection of control and clodronate liposomes. Representative images of, spleen (a and b) liver (c 
and d) and femoral bone marrow (e and f) are shown. 
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Supplemental Figure 4. Differentiated THP1 cells bind asparaginase 
Histograms showing binding of asparaginase to differentiated THP-1 cells. PMA induced differentiated cells 
were incubated with different concentrations of FITC-labeled asparaginase  at different temperatures. 
Binding was analyzed by flowcytometry.  
Supplemental Figures 
S5A 
β-tubulin 
Cathepsin B 
+ - + - + - + - + - differentiation 
S5B 
Supplemental Figure 5. Cathepsin B protein expression and activity in THP-1 cells 
A Western blot analysis of Cathepsin B protein expression in undifferentiated and PMA induced 
differentiated THP-1 cells transduced with shRNAs targeting Cathepsin B or control, non-targeting (NT) 
shRNA. β-tubulin was used as a control for equal loading. 
B Cathepsin B activity in lysates of differentiated THP-1 cells transduced with control or Cathepsin B targeting 
shRNAs, was determined by measuring cleavage of the fluorescent substrate Ac-RR-AFC. The plot shows an 
average of 2 experiments with standard deviation. One of the control samples was set to 1 and all samples 
were correlated to this sample. Unpaired two-tailed t-test was used to determine significance compared to 
parental cells * = p < 0.05, ** = p < 0.01. 
Supplemental tables 
Supplemental Table 1  
Sequences of the shRNA constructs. Seed sequences are underlined. 
shRNA Hairpin sequence 
Non-targeting shRNA  CACCCAACAAGATGAAGAGCACCAACGAATTGGTGCTCTTCATCTTGTTG 
Cathepsin B shRNA #1 CCGGCCAGAGAGTTATGTTTACCGACTCGAGTCGGTAAACATAACTCTCTGGTTTT
T 
Cathepsin B shRNA #2 CCGGGACAAGCACTACGGATACAATCTCGAGATTGTATCCGTAGTGCTTGTCTTTT
T 
Cathepsin B shRNA #3 CCGGCCAACACGTCACCGGAGAGATCTCGAGATCTCTCCGGTGACGTGTTGGTTTT
T 
 
 
Supplemental table 2  
Sequences of RT-qPCR primers 
Gene  Sequence 
CTSB (human) Forward 
Reverse 
CTTGAAGAGGCTATGTGGTACC 
CCCTGGTCTCTGATCTCTTTG 
TBP (human) Forward 
Reverse 
GCACAGGAGCCAAGAGTGAA 
ACATCACAGCTCCCCACCAT 
Ctsb (mouse) Forward 
Reverse 
ACAAGCCTTCCTTCCACCCG 
TGTCCTCACCGAACGCAACC 
Hprt (mouse) Forward 
Reverse 
GGGGGCTATAAGTTCTTTGCTGACC 
TCCAACACTTCGAGAGGTCCTTTTCAC 
 
 
 
Supplemental methods 
 
Radiolabeling of asparaginase 
Asparaginase (4 mg) was conjugated under strict metal-free conditions with isothiocyanatobenzyl–
diethylenetriaminepentaacetic acid (ITC-DTPA, Macrocyclics, Dallas, TX) in 0.1 M NaHCO3, pH 9.5, 
using a 10-fold molar excess of ITC-DTPA. After 1 hour incubation at RT the conjugation mixture was 
dialyzed in a dialysis cassette with a molecular cut-off value of 20 kDa (Slide-A-Lyzer 20K, Thermo 
Scientific, Waltham, MA) against 0.25 M Ammonium Acetate, pH 5.5 to remove the unconjugated 
ITC-DTPA. The substitution ratio, as determined by labeling the conjugation mixture with 111InCl3 
(600-800 MBq, Mallinckrodt, Petten, The Netherlands), was 0.8 DTPA/asparaginase molecule. 111InCl3 
was added to DTPA-asparaginase (50-65 μg) for 1 h at RT in 0.1 M 2-(N-morpholino)ethanesulfonic 
acid buffer, pH 5.4. Free In-111 was complexed by adding 50 mM ethylenediaminetetraacetic acid 
(EDTA; final concentration of 5 mM). Quality control was performed using instant thin-layer 
chromatography. To obtain a radiochemical purity ≥95%, 111In-labeled protein was purified by gel 
filtration on a disposable PD10 column (GE Healthcare Life Sciences, Eindhoven, the Netherlands), 
eluted with PBS containing 0.5% bovine serum albumin (BSA). The specific activity of the radiolabeled 
asparaginase preparations used in the experiments was (5-12 MBq/μg). 
 
Autoradiography 
Formalin-fixed, paraffin-embedded tissue sections (4 μm) from mice injected intravenously with 
111In-asparaginase were dewaxed, rehydrated and exposed to a phosphor imaging screen for up to 7 
days. The screen was scanned in a phosphor imager system (Bioimaging Analyzer System 1800-II; 
Fujifilm, Tilburg, the Netherlands) at a pixel size of 50 × 50 μm. 
 Asparaginase binding assay 
Human peripheral blood mononuclear cells (PBMCs) were isolated from blood obtained from healthy 
volunteers upon informed written consent, using density gradient centrifugation (Lymphoprep; Axis-
Shield, Dundee, Scotland). Asparaginase (Takeda, Hoofddorp, the Netherlands) was conjugated with 
Fluorescein isothiocyanate according to manufacturer’s instructions (Pierce / Life Technologies, 
Carlsbad, CA). PBMCs or THP-1 cells were incubated with FITC labeled asparaginase in culture 
medium for 1 hour at the indicated temperatures. After incubation, PBMCs were stained for 
expression of lineage markers with anti-CD14, -CD45, -CD3 and -CD19 antibodies purchased form BD 
Biosciences and analyzed using a LSRII flow cytometer (BD Biosciences, Breda, the Netherlands). The 
data were collected and analyzed by FlowJo software version 8.8.7 FlowJo, Ashland OR). 
 
Immunohistochemistry 
For histological analysis, tissues and organs, including spleen, lymph nodes, thymus, liver and 
femur/tibia were fixed in 4% formalin during 24 hours. Bone containing tissues were decalcified using 
Osteosoft (Merck Laboratories). Specimens were embedded in paraffin, 4 µM serial sections were cut 
and stained with hematoxylin and eosin (HE) following standard procedures. After dewaxing, 
rehydration and antigen retrieval using sodium citrate, slides were blocked with 2% normal goat 
serum (Vector Laboratories, Burlingame, CA) and 2% BSA in 0.05% PBS, Tween20 prior to overnight 
staining with F4/80 (MCA497GA, AbD Serotec, Oxford, United Kingdom) and Asparaginase (ab21013, 
Abcam, Cambridge, United Kingdom) antibodies. Appropriate biotinylated antibodies (Vector 
Laboratories) were used as secondary antibody and staining was revealed by incubation with metal-
enhanced diaminobenzidine in stable peroxide substrate buffer (Thermo Fisher Scientific Inc.). After 
counterstaining with hematoxylin (1:3) sildes were dehydrated and coverslipped using entellan 
(Merck Laboratories). Images were captured using a VisionTek digital microscope (Sakura Finetek, 
Torrance, CA). 
 
Cell culture 
The human acute monocytic leukemia cell line THP-1 was obtained from the American Type Culture 
Collection (ATCC, #TIB-202) cultured in RPMI 1640 containing L-glutamine (Invitrogen /Life 
technologies), supplemented with 10% heat-inactivated fetal bovine serum (Greiner Bio-One), and 
100 units/ml penicillin/streptomycin (Invitrogen). The mouse leukemic monocyte macrophage cell 
line RAW264.7 (ATCC #TIB-71) and HEK293 FT (Invitrogen) cells were cultured in DMEM containing L-
glutamine (Invitrogen), supplemented with 10% heat-inactivated fetal bovine serum, 100 units/ml 
penicillin/streptomycin, and 1% non-essential amino acids (Invitrogen). All cells were incubated at 
37°C in a 5% CO2 humidified atmosphere.  All cell Lines were used within 3 months of culture. THP-1 
differentiation was induced by culturing 5 – 8 x 106 cells in the presence of 100 nM phorbol myristate 
acetate (PMA; Sigma-Aldrich) for three days. After three days the medium was refreshed by medium 
without PMA and terminal differentiation was continued for an additional three days.  
 
Real-time Quantitative Polymerase Chain Reaction 
Total RNA was extracted using the RNeasy mini-kit (Qiagen, Venlo, the Netherlands) according to 
manufacturer’s instructions. Subsequently, cDNA was synthesized of 500 ng RNA template using the 
iScriptTM cDNA synthesis kit (Bio-Rad, Hercules, CA). mRNA expression levels were determined by 
use of Power SYBR® Green PCR master mix using gene-specific primers (sequences are listed in 
Supplemental Table 2) and the CFX96 TouchTM Real-Time PCR detection system (Bio-Rad). TBP 
mRNA expression was used as a reference to obtain the relative fold expression of target genes using 
the comparative cycle threshold 2(-ΔΔCt) method. Prism software (Graphpad, La Jolla, CA) was used to 
plot the data and for statistical analysis. p< 0.05 was considered a significant difference. 
 Immunoblotting 
Whole cell extracts were prepared in NP-40 lysis buffer (200 mM NaCl, 0.5% NP-40, 20 mM Tris-HCl, 
pH 8.0, 5 mM EDTA) and cleared by centrifugation. Protein lysates were resolved by sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a polyvinylidene difluoride 
(PVDF) membrane. The membranes were probed with primary antibodies against cathepsin B (sc-
13985, Santa Cruz Biotechonology, Dallas, TX) or β tubulin (#2128, Cell Signalling Technology, Leiden, 
the Netherlands), followed by horseradish peroxidase (HRP) conjugated secondary antibody (DAKO, 
Heverlee, Belgium). Proteins were visualized with ECL reagent (GE Healthcare) and expression was 
detected with Fluorchem (Protein Simple, San Jose, CA). 
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